News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
179,486 Results
Type
Article (13074)
Company Profile (26)
Press Release (166386)
Multimedia
Podcasts (9)
Webinars (5)
Section
Business (49844)
Career Advice (622)
Deals (9283)
Drug Delivery (30)
Drug Development (28418)
Employer Resources (71)
FDA (4731)
Job Trends (4009)
News (92865)
Policy (8045)
Tag
2024 BioMidwest Digital (2)
2024 Bio NC Digital (1)
2024 Biotech Bay Standard (4)
2024 Biotech Beach Standard (1)
2024 Genetown Standard (2)
2024 Pharm Country Standard (2)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (1)
Academia (1123)
Academic (1)
Accelerated approval (1)
Adcomms (6)
Allergies (31)
Alliances (14007)
ALS (40)
Alzheimer's disease (442)
Antibody-drug conjugate (ADC) (22)
Approvals (4745)
Artificial intelligence (64)
Autoimmune disease (8)
Automation (3)
Bankruptcy (71)
Best Places to Work (3355)
BIOSECURE Act (6)
Biosimilars (34)
Biotechnology (14)
Bladder cancer (22)
Brain cancer (8)
Breast cancer (82)
Cancer (584)
Cardiovascular disease (61)
Career advice (524)
Career pathing (13)
CAR-T (45)
Cell therapy (110)
Cervical cancer (10)
Clinical research (24137)
Collaboration (178)
Compensation (20)
Complete response letters (1)
COVID-19 (1111)
CRISPR (8)
C-suite (54)
Cystic fibrosis (27)
Data (718)
Denatured (6)
Depression (11)
Diabetes (92)
Diagnostics (1740)
Digital health (4)
Diversity (5)
Diversity, equity & inclusion (29)
Drug discovery (37)
Drug pricing (38)
Drug shortages (16)
Duchenne muscular dystrophy (32)
Earnings (14617)
Editorial (16)
Employer branding (5)
Employer resources (65)
Events (21585)
Executive appointments (192)
FDA (5063)
Featured Employer (12)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (2)
Funding (205)
Gene editing (17)
Generative AI (6)
Gene therapy (86)
GLP-1 (265)
Government (1232)
Grass and pollen (1)
Guidances (10)
Healthcare (5891)
Huntington's disease (6)
IgA nephropathy (9)
Immunology and inflammation (31)
Indications (6)
Infectious disease (1155)
Inflammatory bowel disease (53)
Inflation Reduction Act (4)
Influenza (14)
Intellectual property (16)
Interviews (104)
IPO (3532)
IRA (19)
Job creations (778)
Job search strategy (461)
Kidney cancer (4)
Labor market (6)
Layoffs (79)
Leadership (7)
Legal (1563)
Liver cancer (26)
Lung cancer (62)
Lymphoma (41)
Machine learning (1)
Management (23)
Manufacturing (68)
MASH (32)
Medical device (3296)
Medtech (3298)
Mergers & acquisitions (5900)
Metabolic disorders (210)
Multiple sclerosis (38)
NASH (15)
Neurodegenerative disease (23)
Neuropsychiatric disorders (5)
Neuroscience (628)
NextGen: Class of 2025 (2144)
Non-profit (1762)
Northern California (514)
Obesity (96)
Opinion (51)
Ovarian cancer (15)
Pain (31)
Pancreatic cancer (22)
Parkinson's disease (55)
Partnered (7)
Patents (28)
Patient recruitment (36)
Peanut (17)
People (17686)
Pharmaceutical (11)
Pharmacy benefit managers (9)
Phase I (5386)
Phase II (10418)
Phase III (9825)
Pipeline (295)
Policy (53)
Postmarket research (1152)
Preclinical (1934)
Press Release (29)
Prostate cancer (35)
Psychedelics (15)
Radiopharmaceuticals (67)
Rare diseases (117)
Real estate (1450)
Recruiting (23)
Regulatory (5887)
Reports (13)
Research institute (966)
Resumes & cover letters (82)
Rett syndrome (1)
RSV (18)
Schizophrenia (22)
Series A (46)
Series B (29)
Service/supplier (2)
Sickle cell disease (13)
Southern California (493)
Special edition (3)
Spinal muscular atrophy (62)
Sponsored (4)
Startups (1200)
Stomach cancer (4)
Supply chain (17)
Tariffs (7)
The Weekly (3)
United States (4989)
Vaccines (278)
Venture capitalists (8)
Weight loss (69)
Women's health (14)
Worklife (7)
Date
Today (20)
Last 7 days (106)
Last 30 days (562)
Last 365 days (8325)
2025 (2399)
2024 (8743)
2023 (10032)
2022 (13250)
2021 (14874)
2020 (14639)
2019 (14156)
2018 (10897)
2017 (9635)
2016 (9302)
2015 (10965)
2014 (7484)
2013 (5847)
2012 (6292)
2011 (6672)
2010 (5742)
Location
Africa (260)
Alabama (8)
Alaska (4)
Arizona (41)
Arkansas (3)
Asia (12670)
Australia (2441)
California (1205)
Canada (398)
China (145)
Colorado (54)
Connecticut (53)
Delaware (35)
Europe (33763)
Florida (196)
Georgia (74)
Idaho (14)
Illinois (166)
India (9)
Indiana (88)
Iowa (2)
Japan (66)
Kansas (29)
Kentucky (8)
Louisiana (5)
Maine (11)
Maryland (218)
Massachusetts (887)
Michigan (38)
Minnesota (87)
Missouri (17)
Montana (6)
Nebraska (6)
Nevada (17)
New Hampshire (10)
New Jersey (447)
New Mexico (7)
New York (487)
North Carolina (179)
Northern California (514)
Ohio (38)
Oklahoma (3)
Oregon (6)
Pennsylvania (291)
Puerto Rico (3)
Rhode Island (4)
South America (380)
South Carolina (7)
Southern California (493)
Tennessee (19)
Texas (152)
Utah (23)
Virginia (28)
Washington D.C. (6)
Washington State (161)
Wisconsin (10)
179,486 Results for "compass group".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
April 3, 2025
·
1 min read
Press Releases
Compass Pathways to Participate in Stifel Virtual CNS Forum
March 11, 2025
·
1 min read
Layoffs
Compass Delays Pivotal Trial Readouts for Psilocybin in Depression, Lays Off 30% of Staff
In another delay for the psychedelic treatment space, Compass Pathways announced adjusted timelines for two Phase III trials of its psilocybin to address treatment-resistant depression.
October 31, 2024
·
2 min read
·
Heather McKenzie
Press Releases
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression
March 18, 2025
·
8 min read
Press Releases
Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer
April 21, 2025
·
5 min read
Press Releases
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update
February 27, 2025
·
9 min read
Press Releases
Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference
February 25, 2025
·
1 min read
Press Releases
Compass Pathways Announces Pricing of Underwritten Offering
January 10, 2025
·
6 min read
Press Releases
Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
January 29, 2025
·
1 min read
Press Releases
Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights
February 27, 2025
·
11 min read
1 of 17,949
Next
